https://memo-therapeutics.com/  

8952 Schlieren, Wagistrasse 27

 info@memo-therapeutics.com

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology. MemoMAB discovery uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity. MemoMAB captures and preserves entire B cell repertoires from any donor species and any B cell type in recombinant form and displays them in mammalian cells, maintaining the cognate heavy and light chain pairing of the original B cells throughout the process.